Top 20 pharmaceutical companies in 2017

Source: the latest season of e-medicine manager 2018-01-08 "what's your host's ranking"! The good news is that, on the whole, most of the multinational giants began to warm up last year after the market value downturn in 2016, and the market value has increased In 2017, FDA approved 46 new drugs including dukuai gene therapy, which is not only a rare harvest year in history, but also a new high in 20 years The listing of kymriah and yescarta, including car-t therapy, marks the completion of a long process of transformation of these high-tech biotechnologies into the market, and also makes the corresponding enterprises gain more favor in the capital market On the other hand, with the appointment of Scott Gottlieb, the new director of FDA, in addition to the increase in the number of new drugs, it has brought price competition to the US generic drug market According to e-drug managers, the total market value of the world's top 20 pharmaceutical companies reached 2566.77 billion US dollars in 2017 The good news is that, on the whole, the market value of most multinational giants has performed well in the past year and has risen Compared with 2016, only Johnson & Johnson crossed the threshold of $300 billion, and other companies are below the level of $200 billion In 2017, although there is still only one Johnson & Johnson club with $300 billion, the market value including Novartis, Roche and Pfizer has recovered to more than $200 billion 1 in 2017, Huiwen Johnson & Johnson was still strong, winning the title of market value champion, with an increase of 20% If we follow this trend, we may expect this global giant to break the $400 billion mark in 2018 and set another record Next came Novartis, which jumped 17.6% to second place With the approval of the world's first car-t therapy and the appointment of the new CEO, who is only 41 years old, the next performance of Novartis is also very concerned Roche ranked third with a market capitalization of $224.19 billion, up 13.2% This time, Cosmos Pharmaceutical Co., which is not bad for money, ranked fourth with a market value of $219.29 billion, up 11.26% Pfizer, which did not sell in the M & a market in 2017, is sure to achieve something this year with the signing of the US tax reform act Whether it's a biological upstart such as BMS and Baijian, or the century merger and acquisition with Elgin, Pfizer's strength deduces "money is also a business model" Aberdeen is one of the most impressive companies on the market capitalization list It took five years for Alberto to triple its market value since it was spun off from Abbott in 2013 This achievement also allowed him to surpass other biological upstarts and old brand pharmaceutical giants, following the big four Recently, the aibowei all oral direct anti HCV treatment plan weijianle and yiqirui were officially listed in China, which also added an important weight in the domestic hepatitis C market war In 2017, the market value of three companies declined, namely MSD, GSK and Xinji According to the third quarter 2017 financial report released by MSD, the revenue was US $10.325 billion, down 2% year-on-year, due to the decline in the revenue of Jiada Xiu, a nine price HPV vaccine, etc New base's most interesting cooperation last year is undoubtedly the cooperation with Baiji, which not only set a record in product licensing, but also took over the business and team of new base China in an all-round way This year, Emma, Global CEO of GSK, made a restructuring plan after taking office, focusing 80% of the R & D cost on two core treatment areas: respiratory disease and HIV / infectious disease, and two potential treatment areas: immune inflammation and tumor Obviously, the traditional strength of GSK in the field of central nervous system is not in her future plan This restructuring plan also affected GSK's R & D center in China and made corresponding strategic adjustments From the global top 20, let's compare the market value of Chinese pharmaceutical companies horizontally According to the latest data, Hengrui still leads the Chinese pharmaceutical listed companies with a market value of 80 billion yuan That's about $10 billion from the threshold of last year's list In fact, 2017 is a year of rapid growth for the market value of China's pharmaceutical listed companies, and the market value of many local listed companies has seen a significant increase, with remarkable performance in this year If Hengrui can achieve steady growth, it is believed that in the next two or three years, Chinese enterprises will take a place in the global top 20 pharmaceutical market value list Of course, for pharmaceutical companies, market value is only a reference If they want to have a place in the market environment where the general growth has slowed down, the most important thing is a strong product line and management operation management For Chinese enterprises, from the perspective of globalization, there is still a long way to go